A similar tumor growth bypass pathway was also found in breast cancer; Castel et al. (54) showed that PDK1-SGK1 signaling sustained AKT-independent mTORC1 activation and confers resistance to PI3Kα inhibition, indicating that either PDK1 or SGK1 blockade prevents mTORC1 activation and restores the antitumoral effects of PI3Kα inhibition in resistant cells. Here, SGK1 is linked to breast carcinoma.